Acute intermittent hypoxia (AIH) induces a form of spinal motor plasticity known as phrenic long-term facilitation (pLTF); pLTF is a prolonged increase in phrenic motor output after AIH has ended. In anesthetized rats, we demonstrate that pLTF requires activity of the novel PKC isoform, PKC, and that the relevant PKC is within phrenic motor neurons. Whereas spinal PKC inhibitors block pLTF, inhibitors targeting other PKC isoforms do not. PKC is highly expressed in phrenic motor neurons, and PKC knockdown with intrapleural siRNAs abolishes pLTF. Intrapleural siRNAs targeting PKC, an atypical PKC isoform expressed in phrenic motor neurons that underlies a distinct form of phrenic motor plasticity, does not affect pLTF. Thus, PKC plays a critical role in spinal AIH-induced respiratory motor plasticity, and the relevant PKC is localized within phrenic motor neurons. Intrapleural siRNA delivery has considerable potential as a therapeutic tool to selectively manipulate plasticity in vital respiratory motor neurons.
Introduction
Our appreciation for spinal motor plasticity and its role in functional recovery from motor deficits caused by neural injury has increased in recent years (Wolpaw and Tennissen, 2001; Kokotilo et al., 2009; Dale-Nagle et al., 2010b) . Prominent models of spinal plasticity include operant conditioning of the H reflex (Wolpaw et al., 1986) , spinal instrumental learning (Grau et al., 2006) , spontaneous phrenic motor recovery below a cervical hemisection (Goshgarian, 2009) , and phrenic long-term facilitation (pLTF) following acute intermittent hypoxia (AIH) ). Basic insights into spinal plasticity have guided preclinical trials demonstrating that intermittent hypoxia increases leg strength, walking time, and walking speed in patients with incomplete spinal injuries (Trumbower et al., 2012; Hayes et al., 2014) .
The phrenic motor system is ideal to study spinal motor plasticity because rhythmic phrenic nerve activity is readily quantified and reflects a meaningful, automatic motor behavior that exhibits functional plasticity (Feldman et al., 2003; Mitchell and Johnson, 2003) . The most frequently studied model of respiratory motor plasticity is pLTF, a prolonged increase in phrenic burst amplitude lasting hours following AIH (Hayashi et al., 1993; Bach and Mitchell, 1996) . Studies of pLTF continue to guide therapies with intermittent hypoxia to restore motor function Lovett-Barr et al., 2012; Nichols et al., 2013 ), but we still have an incomplete understanding of the mechanisms giving rise to this important form of spinal plasticity.
Hypoxia activates medullary raphe neurons, increasing serotonin release within spinal respiratory motor nuclei (Kinkead et al., 2001) . Episodic spinal serotonin Type 2 receptor activation is necessary (Fuller et al., 2001a; Baker-Herman and Mitchell, 2002) and sufficient MacFarlane et al., 2011) for pLTF, triggering new synthesis of BDNF. New BDNF synthesis is necessary, and spinal TrkB receptor activation is sufficient to elicit pLTF (Baker-Herman et al., 2004) via downstream ERK MAP kinase signaling . Molecular elements linking serotonin receptor activation to downstream signaling likely involve protein kinase C (PKC) because of its strong coupling to serotonin Type 2 receptors and its role in other forms of neuroplasticity (Hua et al., 1999; Sossin, 2007) . Thus, we wished to determine whether spinal PKC activity is necessary for AIH-induced pLTF, and to identify which of the 15 known PKC mammalian isoforms is involved.
Another major goal of this study was to localize the plasticity to the critical spinal cellular elements, often hypothesized to be phrenic motor neurons Feldman et al., 2003) . To our knowledge, no studies have directly demonstrated that mammalian lower motor neurons are plastic. Motor plasticity known as sensorimotor long-term facilitation occurs in the sea slug, Aplysia, following tail stimulation or episodic serotonin receptor activation (Mauelshagen et al., 1998; Glanzman, 2009) . Critical molecular events for this form of plasticity occur in the presynaptic sensory neuron (Kandel, 2001 ). However, protein synthesis, intracellular calcium elevation, and AMPA receptor insertion have been demonstrated in Aplysia postsynaptic motor neurons following induction of long-term facilitation (Cai et al., 2008; Glanzman, 2008) . These studies suggest that motor neurons are malleable and lend credence to our hypothesis that mammalian spinal ␣ motor neurons, which have long been thought of as of as "relays" between the CNS and muscles, are indeed highly plastic. Using spinal injections of differentially selective PKC inhibitors, immunofluorescence to confirm PKC expression in phrenic motor neurons, and RNA interference via intrapleural injections of siRNAs (Mantilla et al., 2013) targeting PKC mRNA within phrenic motor neurons, we test three hypotheses: (1) spinal PKC activity is necessary for pLTF; (2) the relevant PKC isoform is PKC; and (3) PKC is expressed within phrenic motor neurons. These studies provide the first evidence for a critical role of PKC in any form of motor plasticity and demonstrate that the relevant PKC is within the motor neurons per se.
Materials and Methods
Animals. Experiments were performed on 3-to 4-month-old male Sprague Dawley rats (Harlan colony 211 or 218a) weighing 280 -480 g. Rats were housed two per cage with food and water ad libitum and kept in a 12 h light/dark cycle. All protocols were approved by the Institutional Animal Care and Use Committee at the University of WisconsinMadison and conformed to policies found within the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Drugs
Pharmacological solutions. Bisindolymalemide I, 1.4 mM (BIS, also known as GF109203X or Gö 6850; Tocris Biosciences), 40 mM Gö 6983 (Tocris Biosciences), 50 mM CID755673 (CID; Sigma-Aldrich), and 20 mM sotrastaurin (also known as AEB 071; Axon ligands) were dissolved in DMSO and stored at Ϫ20°C. Myristoylated peptide (2 g/l) mimicking the pseudosubstrate domain of PKC (theta inhibitory peptide, TIP; Calbiochem) dissolved in ACSF (in mM as follows: 120 NaCl, 3 KCl, 2 CaCl, 2 MgCl, 23 NaHCO 3 , 10 glucose; 95% O 2 /5% CO 2 ) and stored at Ϫ20°C. NPC15437, 50 mM (NPC; Sigma-Aldrich) was stored in ACSF at 4°C. All PKC inhibitors were chosen based on published half-maximal inhibitory concentrations (Martiny-Baron et al., 1993; Gschwendt et al., 1996; Uberall et al., 1997; Saraiva et al., 2003; Felber et al., 2007; Sharlow et al., 2008; Evenou et al., 2009) .
Intrathecal injections. Drugs were delivered at doses consistent with spinal inhibition of PKC (Yashpal et al., 1995; Hua et al., 1999; Ferguson et al., 2008; Laferrière et al., 2011) . Stock solutions were diluted in ACSF to their final concentration with a DMSO concentration between 0% and 20% (Gö 6983 20%; NPC 0%; CID 10%; BIS 20%; sotrastaurin 10%; TIP, 0%). In some cases, Gö 6983 in 100% DMSO or 100% DMSO alone (vehicle) was delivered intrathecally due to limited drug solubility. Limited dose-response curves are shown in Figure S1 (available at www. jneurosci.org as supplemental material). A 50 l Hamilton syringe was loaded with drug solution and connected to silicone catheter (2 Fr Access Technologies; 0.3 mm inner diameter) inserted subdurally above C 4 spinal segment. Injections were delivered 10 -15 min before AIH (12 l total, 2 l/30 s). Vehicle-treated rats received ACSF with 0%-100% DMSO. There was no difference in pLTF when pretreated with 100% DMSO versus ACSF (47 Ϯ 15% vs 44 Ϯ 3%, respectively; p ϭ 0.70).
RNA interference siRNA delivery. Pools of four 21-nucelotide duplexes of Accell-modified small interfering RNAs (siRNAs) targeting PKC (siPKC), PKC (siPKC), and nontargeting (NTsiRNA) were purchased from Dharmacon (Thermo Scientific). Accell-modified siRNA was chosen because this modification preferentially transfects neurons versus other cell types (Nakajima et al., 2012) . Each siRNA pool was suspended in Dharmacon siRNA buffer to yield a concentration of 5 M, aliquoted, and stored at Ϫ20°C. Before intrapleural injections, 20 l of siRNA was added to 6 l of 5ϫ siRNA buffer (Dharmacon), 3.2 l of Oligofectamine Transfection Reagent (Invitrogen) and 0.8 l of RNAase free H 2 O (final siRNA concentration of 3.33 M) and carefully mixed 20 min before injection, allowing the siRNA to complex with the transfection reagent.
Intrapleural injections. Bilateral intrapleural injections of siRNAs and cholera toxin B (CtB) fragment were performed as previously described (Mantilla et al., 2009 (Mantilla et al., , 2013 . Rats were induced in a flow-through chamber with 5% inhaled isoflurane in 100% O 2 , placed on a surgical table, and maintained with a nose cone (2% isoflurane, 100% O 2 ). For phrenic motor neuron back labeling, a 25 l Hamilton syringe with attached sterile needle (6 mm) was loaded with 12.5 l of CtB fragment (2 g/l in sterile H 2 O) per side. For intrapleural siRNA delivery, 30 l was loaded into a 50 l Hamilton syringe. The rib cage was palpated to locate the fifth intercostal space at the anterior axillary line, and the needle was inserted into the pleural space bilaterally to deliver the injectate. After injections, isoflurane was discontinued and respiratory chest movements were monitored for at least 15 min after discontinuing anesthesia. All rats recovered with minimal signs of distress.
Phrenic nerve recordings
Surgical preparation. Surgical procedures for phrenic and hypoglossal nerve isolation were performed as described previously (Bach and Mitchell, 1996; Fuller et al., 2001a) . Briefly, rats were induced in a closed chamber with isoflurane, placed on an experimental surgical table, and maintained with a nose cone (3.5% isoflurane, 50% O 2 ). After performing a tracheotomy, rats were pump ventilated (Rodent Ventilator 683, Harvard Apparatus; tidal volume 2.2-2.7 ml; frequency 70 -75 breaths/ min) with 3.5% isoflurane in 50% O 2 (balance N 2 ). Small amounts of CO 2 were added to the gas mixture to maintain end-tidal CO 2 (Respironics Novametrix) at 42-45 mmHg. Tracheal pressure was monitored to prevent overinflation and to assure that the tracheostomy remained patent. Both vagus nerves were isolated in the mid-cervical region and cut bilaterally to prevent ventilator entrainment. A tail vein was catheterized for continuous delivery of intravenous fluids (ϳ1.5 ml/h of 75% lactated Ringer's solution, 10% HCO 3 , and 15% hetastarch; Hespan, 6% hetastarch in 0.9% NaCl). Intravenous fluid infusion was adjusted as needed to maintain acid-base status (Ϫ4.0 to 4.0 mEq/L base excess, Յ1.5 mEq/L change at 60 min) as determined via blood samples. Catheterization of the femoral artery was performed for blood gas sampling and blood pressure recording. The left hypoglossal and phrenic nerves were isolated using a dorsal approach, cut, desheathed, and covered with saline-soaked cotton. A C 2 laminectomy was performed for intrathecal drug administration; the dura was exposed, cut dorsally, and a silicone catheter (2 Fr; Access Technologies) attached to a 50 l Hamilton syringe was advanced under the dura to C 4 . Anesthesia was then slowly converted to urethane (1.8 -2.0 mg/kg, i.v.) while isoflurane was slowly withdrawn. After sufficient time for isoflurane dissipation, rats were paralyzed with pancuronium bromide (2.5 mg/kg, i.v.). Body temperature was measured with rectal probe and kept at 37.5 Ϯ 1°C using the heated surgical table. Blood pressure was monitored throughout the experiment to ensure physiological stability (baseline: 70 -150 mmHg, Յ30 mmHg change at the end of an experiment). Depth of anesthesia was assessed by toe pinch responses in blood pressure and phrenic nerve activity. At the end of each protocol, a maximal CO 2 response (end-tidal CO 2 Ͼ 90 mmHg) was assessed to verify adequate dynamic range for phrenic output. All rats included in the study had Ͼ30% hypoxic response during AIH and Ͼ50% maximal hypercapnic response at 60 min after AIH (or sham normoxia), signifying that neither chemosensory inputs nor phrenic motor output was saturated. All rats were sacrificed at the end of neurophysiological experiments with an intravenous urethane bolus.
Electrophysiology. Desheathed phrenic and hypoglossal nerves were placed on bipolar silver electrodes and submerged in mineral oil to prevent dessication. Nerve activity was amplified (10,000ϫ), bandpass filtered (300 -10,000 Hz model 1800, A-M Systems), rectified and integrated with a continuous moving averager (time constant: 50 ms; CWE, MA-821 filter). The integrated signal was digitized and analyzed with a data acquisition system (WINDAQ,DATAQ Instruments).
One hour following conversion to urethane anesthesia, the CO 2 apneic and recruitment thresholds for phrenic nerve activity were determined by adjusting inspired CO 2 and/or ventilator frequency. Baseline CO 2 was maintained at 2-3 mmHg above the recruitment threshold for the duration of an experiment. Baseline nerve activity was maintained for at least 20 -30 min, and then a blood sample was drawn to measure arterial PCO 2 , PO 2 , and pH to assess "baseline" conditions. Some rats received intrathecal injections near the phrenic motor nucleus 10 -15 min before beginning experimental paradigms. The rats were then exposed to either AIH or continuous baseline conditions (i.e., time control). AIH consisted of three 5 min episodes of 10%-12% inspired O 2 , separated by 5 min of baseline oxygen conditions. During hypoxic episodes, arterial P O2 was between 35 and 45 mmHg, and arterial P CO2 was maintained within 1.5 mmHg of baseline values. Following AIH, baseline conditions were reestablished. Blood gas analyses were performed at 15, 30, and 60 min after AIH; blood inclusion criteria included arterial PO 2 Ͼ 180 mmHg, PaCO 2 within 1.5 mmHg of baseline, and base excess within 1.5 mEq/L of baseline. All rats had blood values within this range. Additionally, rats that had short-term hypoxic responses of Ͻ50% increase from baseline were eliminated from the study (only one rat did not meet this criterion).
Rats treated as time controls received relevant pharmacological agents but did not receive AIH and were maintained at baseline conditions for an equivalent period. Blood samples were taken at similar times as AIHtreated rats.
Protein quantification
Tissue harvesting. After electrophysiology experiments, a C 2 -C 5 laminectomy was performed and rats were partially exsanguinated. The spinal cord was cut at the C 3 (mid C 3 ) and C 6 rootlets (mid C 6 ), and then placed on ice. After allowing the extracted spinal cord to cool for 1 min, a coronal cut was made separating dorsal and ventral cord. The ventral cord was placed in a Pyrex homogenizer (Corning, 1 ml PTFE Pestle Tissue Grinder) filled with 250 l of homogenization buffer (150 mM NaCl, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0 with 1ϫ Halt Phosphatase Inhibitor mixture, Thermo Scientific; and 1ϫ Protease Inhibitor Mixture, Sigma-Aldrich #P8340) and homogenized by pumping 20 times. The sample was then spun for 10 min at 0.5 relative centrifugal force. The pellet was discarded; 12 l of the supernatant was saved for bicinchoninic acid assay for protein. The remaining supernatant was transferred and mixed with an equal volume of 2ϫ loading buffer (5% 2-mercaptoethanol in Laemmli buffer: 65.8 mM TrisHCl, pH 6.8, 2.1% SDS, 26.3% (w/v) glycerol, 0.01% bromophenol blue). Both samples were stored at Ϫ20°C for protein analysis and immunoblotting. Right diaphragm samples were also taken from each rat and processed in the same manner as above, except that 500 l of homogenization buffer was used in a 3 ml tissue grinder.
Immunoblotting. Bicinchoninic acid protein assay was performed using the Thermo Scientific Pierce BCA Protein Assay Kit following manufacturer's instructions. Using the estimated protein concentration, each sample was diluted to 1 g protein/l with loading buffer before loading into 10% or 4%-15% Tris-HCl 18 well gels. The 25 l/well of loading control (1:1 loading buffer and homogenization buffer) and 10 -25 l/ well of a protein ladder (1:1:1 of loading buffer, Precision Plus Protein Dual Color Standard, Bio-Rad; and Biotinylated Protein Ladder, Cell Signaling Technology) were also loaded on each gel. The 25 l (25 g protein) of sample was loaded into each well and was run at 120 V for 1 h. Afterward, wet transfer to a 0.45 m pore Immobilon PVDF membrane was performed on ice for 1 h at 100 V. After transfer, the blots were cut at 50 kDa to allow for concurrent separate probing of GAPDH for loading control (MW 37 kDa) and PKC (MW 80 kDa) or PKC (MW 75 kDa). Blots were blocked in 5% BSA (for PKC antibody) or 5% milk (for PKC antibody or GAPDH antibody) in Tris-buffered saline (20 mM Tris, 500 mM NaCl) with 0.05% Tween (TBST) for 1 h at room temperature. Antibodies were then added to the blocking solution, and the blots were incubated overnight at 4°C. Afterward, blots were washed 3 times (5 min) with TBST and probed with HRP-conjugated goat anti-rabbit antibodies (1:10000, Santa Cruz Biotechnology) in blocking solution for 1 h at room temperature. Blots were then washed 5 times (5 min) with TBST. Signal was resolved using Pierce Super Signal West Dura Extended Duration Substrate kit (Thermo Scientific). Chemiluminescence was detected with an AutoChemi Imaging system (UVP Bio-Imaging Systems) with Labworks 4.6. Densitometry was performed with ImageJ by following instructions found at http://lukemiller.org/index.php/2010/11/ analyzing-gels-and-Western-blots-with-image-j/. All relative protein comparisons are made by normalizing to GAPDH signal for that well and then comparing the relative signal with the mean of the control values. Percentage change calculation: 100 Ϫ (sample PKC signal/sample GAPDH signal)/(mean NTsiRNA samples/GAPDH) ϫ 100 Antibodies. Polyclonal antibodies to phospho-PKC (Cell Signaling Technology, #9377) were used at 1/1000 dilution in 5% BSA TBST to assess PKC protein expression with immunoblotting. We used the phospho-PKC antibody instead of other PKC antibodies because: (1) phospho-PKC was unaffected by AIH; (2) phospho-PKC labeling was significantly better than non-phospho-antibodies; and (3) the same phospho-PKC antibody has been used successfully in other studies to determine PKC expression (Jové et al., 2006; Wei et al., 2010) .
Polyclonal antibodies to atypical PKC (Santa Cruz Biotechnology, PKC/ C-20) were used at 1/1000 dilution in 5% milk to probe for PKC (MW ϳ75 kDa). GAPDH antibody (Cell Signaling Technology, 14C10, #2118) was used in 5% milk at 1/50,000 to assess GAPDH protein expression. Polyclonal rabbit anti-phospho-PKC (1/250, Cell Signaling Technology, #9377), polyclonal donkey anti-CtB (1/5000, EMD Millipore), monoclonal mouse anti-rabbit GFAP (1/500, EMD Millipore), and monoclonal mouse anti-rabbit CD11b (1/200, Serotec), conjugated goat anti-donkey AlexaFluor-495 (1/1000, Invitrogen), and conjugated goat anti-rabbit AlexaFluor-488 (1/500, Invitrogen) were used in immunofluorescence treatments.
Immunofluorescence
Tissue preparation and staining. Following electrophysiology experiments, nine rats were killed and perfused transcardially with 300 -400 ml of chilled 0.01 M PBS followed by 300 -400 ml of chilled 4% PFA ( pH, 7.4).The brain and spinal cord were harvested and immersion fixed in 4% PFA for 8 h (4°C). The tissues were then transferred to 20% sucrose followed by 30% sucrose until the tissues were dehydrated. The 40 m transverse slices were cut using a microtome (SM2000R Leica) from C 3 -C 5 and placed into an antifreeze solution of ethylene glycol:glycerol:01 M PBS (3:3:4) until stained. Free-floating sections were washed with 0.05 M Tris-buffered saline with 0.1% Triton-X (TBS-TX) and blocked with 1.0% BSA for 1 h. The tissues were labeled with rabbit anti-P-PKC (1:250, Cell Signaling Technology), mouse anti-GFAP (1: 500, EMD Millipore), mouse anti-CD11b (1:200 Serotec), and donkey anti-CtB (1:5000, EMD Millipore) at room temperature for 16 h. Slices were washed with TBS-TX and subsequently stained with conjugated donkey anti goat AlexaFluor-647 (1:1000, Invitrogen), conjugated donkey anti-rabbit AlexaFluor-488 (1:500, Invitrogen), and donkey antimouse AlexaFluor-695 (1:1000, Invitrogen) for 2 h at room temperature. Tissue slices were washed a final time with TBS-TX and mounted on charged slides with an anti-fade solution (Prolong Gold, Invitrogen).
Imaging. Slices were imaged at 20ϫ and 40ϫ with a Nikon C1 laser scanning confocal microscope with strobing in the Nikon EZ-C1 Gold (version 3.80) confocal imaging software. For z-stacks, 2 m step increments were used.
Statistical analysis
Integrated phrenic burst amplitude and frequency were analyzed in 60 s bins before, during, and 15, 30, and 60 min after AIH or at similar points in time controls (no AIH). Integrated nerve burst amplitudes were expressed as a percentage change from baseline. Two-way ANOVA with a repeated-measures design (Sigmaplot 12) was used to compare integrated nerve burst amplitudes and frequency (as well as arterial PCO 2 , PO 2 , pH, and base excess) to detect significant treatment (AIH vs time control; drug treatment) and time effects. Individual comparisons between groups and times were made via post hoc analysis using Fisher's LSD test. Values of p Ͻ 0.05 were considered statistically significant.
Because no significant differences were found among the different time control experiments (NPC, n ϭ 3; BIS, n ϭ 3; sotrastaurin, n ϭ 2; TIP, n ϭ 4 vehicle, n ϭ 3; p ϭ 0.59), all time control experiments were grouped for comparison with AIH-treated rats. Similarly, because differences were not observed between time control experiments with intrapleural siPKC (n ϭ 3), siPKC (n ϭ 3), and NTsiRNA (n ϭ 4) ( p ϭ 0.43), all intrapleural siRNA injection time controls were grouped.
Results

pLTF requires spinal PKC activity
To test the hypothesis that spinal PKC activation is necessary for pLTF, and to begin identification of the specific PKC isoform(s) involved, six PKC inhibitors with different pharmacological profiles were delivered intrathecally over the phrenic motor nucleus at C 4 before AIH; reported half-maximal inhibitory concentration (IC 50 ) values for each inhibitor and PKC isoform are shown in Table 1 . Short-term hypoxic phrenic responses were unaltered by any spinal PKC inhibitor (data not shown, p Ͼ 0.05), consistent with prior studies using intrathecal pharmacology .
Time-compressed phrenic neurograms (Fig. 1A ) illustrate integrated phrenic nerve burst amplitude before, during, and after AIH. In control rats (Fig. 1A, top, vehicle) , phrenic nerve burst amplitude was significantly elevated above baseline at 30 min (29 Ϯ 4%, p Ͻ 0.05) and 60 min (47 Ϯ 4%, p Ͻ 0.001) after AIH, an effect not observed in time controls (i.e., no AIH; 8 Ϯ 4% at 60 min, p Ͼ 0.05; Fig. 1A, bottom) ; persistent elevation of phrenic nerve burst amplitude represents pLTF.
pLTF does not require classical PKC isoforms
Gö 6983 is a broad-spectrum PKC active-site inhibitor that potently inhibits all classical PKC isoforms (Table 1) (Gschwendt et al., 1996) . Rats pretreated with intrathecal Gö 6983 exhibited significant pLTF at 60 min (46 Ϯ 9%; Fig. 1B ) versus time controls (8 Ϯ 4%, p Ͻ 0.05), which was similar to vehicle pretreated rats (100% DMSO; 44 Ϯ 15%, p Ն 0.28). There was no dose effect of Gö 6983 on pLTF in the range studied ( Fig. 2 ; p Ͼ 0.05).
pLTF requires a novel PKC isoform BIS is a broad-spectrum PKC inhibitor that potently inhibits novel and classical PKC isoforms (Table 1) Because Gö 6983 and BIS are active-site inhibitors, we searched for PKC inhibitors acting by a distinct mechanism. NPC binds PKC regulatory subunits, blocking the binding of its activator, diacylglycerol. Based on in vitro studies, NPC inhibits most PKC isoforms, with some notable exceptions, such as PKC and PKC (Table 1) (Saraiva et al., 2003; Felber et al., 2007) . Surprisingly, rats given 5 mM NPC exhibit qualitatively normal pLTF (Fig. 1A, trace, B ; 54 Ϯ 12%), which is indistinguishable from vehicle controls (47 Ϯ 4%, p ϭ 0.40; Fig. 1B) . Because NPC does not inhibit pLTF at any dose tested (0.1-40 mM, p ϭ 0.61; Fig. 2) , NPC likely does not inhibit the relevant PKC isoform.
Since NPC has no known inhibitory effects on PKC or PKC, we tested inhibitors for these PKC isoforms (Table 1 ). In rats given the PKC inhibitor CID755673, pLTF was indistinguishable from vehicle-treated rats at doses ranging 50 M to 5 mM (40 Ϯ 13%, p ϭ 0.26; Figs. 1B, 2 ). However, a broadspectrum PKC inhibitor that potently inhibits PKC, sotrastaurin, attenuated pLTF at doses Ն2 M (17 Ϯ 4%, p Ͻ 0.001 vs vehicle; Figs. 1B, 2). Because BIS also inhibits PKC, we hypothesized that spinal PKC is the critical PKC isoform for pLTF.
pLTF does not require atypical PKC isoforms
PKC activity is expressed in phrenic motor neurons and required for phrenic motor facilitation induced by inactivity (Strey et al., 2012) . In this same study, PKC inhibition with the myristolated peptide targeting PKC had no effect on pLTF, demonstrating that PKC and PKM are not required for pLTF. Our results fit with this conclusion because Gö 6983, an inhibitor of PKC, had no effect on pLTF (Figs. 1B, 2A ).
pLTF requires PKC activity
Because BIS and sotrastaurin inhibit many PKC isoforms other than PKC, we sought to selectively block PKC activity with a myristolated peptide mimicking the pseudosubstrate region of PKC (TIP). TIP binds to the catalytic domain of PKC, blocking substrate phosphorylation (Harris et al., 1996; Kilian et al., 2004) . Intrathecal TIP (0.86 mM) abolished pLTF (10 Ϯ 7%) versus baseline ( p ϭ 0.17; Fig. 1A ) or time controls (8 Ϯ 4%, p ϭ 0.74; Fig. 1B) . Furthermore, TIP significantly decreased pLTF versus vehicle (47 Ϯ 4%, p Ͻ 0.001; Fig. 1C ) and NPC-treated rats (54 Ϯ 12%, p ϭ 0.001; Fig. 1C ), suggesting that PKC activity per se is necessary for pLTF. pLTF in NPC-treated rats was not significantly different from pLTF in vehicle-treated rats at any time point (16 Ϯ 6% at 15 min, 31 Ϯ 8% at 30 min, 54 Ϯ 12% at 60 min, p ϭ 0.994; Fig. 1C ), yet NPC inhibits all PKC isoforms aside from PKC and PKC (also known as protein kinase D). Because, the PKC inhibitor had no effect on pLTF, we found no evidence that any PKC isoform other than PKC is necessary for AIH-induced pLTF.
PKC is highly expressed in phrenic motor neurons
Because spinal PKC activity appears to be critical for pLTF, we sought to determine cellular expression patterns within the phrenic motor nucleus. Strong PKC labeling (green; Fig. 3 A, C) was observed in labeled phrenic motor neurons (blue; CtBpositive cells; Fig. 3 B, D) and in other, unidentified neurons (higher magnification, Fig. 3F ) in transverse C 4 -C 5 spinal sections. PKC immunolabeling was negligible in microglia (red; CD11b-positive cells; Fig. 3B ) or astrocytes (red; GFAP-positive cells; Fig. 3D ), suggesting that PKC is predominantly expressed in ventral cervical spinal neurons. High-power images of phrenic motor neurons clearly demonstrate immunoreactive PKC protein (Fig. 3E ) colocalized in identified phrenic motor neurons (Fig. 3F ) . 
Classical (␣, ␤, and ␥), novel (␦, , , , ), and atypical PKC isoforms (/, ) are shown. All IC 50 values were obtained from published studies (see Materials and Methods). For NPC, no published IC 50 values are available, but known inhibitory activity is denoted with a plus sign (ϩ). Hyphen (-) indicates no known activity at the particular PKC isoform.
PKC knockdown within phrenic motor neurons blocks pLTF
Intrapleural siRNAs are retrogradely transported to phrenic motor neurons, where they knock down target mRNA and protein levels (Mantilla et al., 2013) . We delivered three daily intrapleural injections of either nontargeting siRNAs (NTsiRNA), or siRNAs targeting PKC (siPKC) or the isoform of atypical PKC (siPKC). PKC is expressed in phrenic motor neurons (Guenther et al., 2010) but is not required for pLTF (Strey et al., 2012) . On the other hand, PKC is necessary for a distinct form of phrenic motor plasticity known as inactivity induced phrenic motor facilitation (Strey et al., 2012) . Rats given NTsiRNA had normal pLTF following AIH (48 Ϯ 12%, p Ͻ 0.001 vs time controls; Fig. 4A, top) , demonstrating that nonspecific effects of the injection procedures, transfection reagent or small, doublestranded RNAs had no impact on pLTF. In contrast, siPKC blocked pLTF (11 Ϯ 13%, p ϭ 0.24 vs time controls, p Ͻ 0.001 vs NTsiRNA; Fig. 4A , middle), confirming that PKC is essential for pLTF and that the relevant PKC is located within phrenic motor neurons per se. pLTF was unaffected in rats given siPKC (57 Ϯ 15%, p Ͻ 0.001 vs time control, p ϭ 0.27 vs NTsiRNA; Fig. 4A , bottom), demonstrating that neither knockdown of this atypical PKC isoform nor nonspecific siRNA effects could account for loss of pLTF after siPKC delivery. In summary (Fig. 4B) , pLTF was normal in rats treated with NTsiRNA or siPKC, whereas siPKC completely blocked pLTF.
Short-term hypoxic phrenic responses were unaltered by siPKC (83 Ϯ 9%) versus NTsiRNA (83 Ϯ 7%, p ϭ 0.70; Fig 5) . Rats treated with siPKC appeared to have enhanced short-term hypoxic phrenic responses versus siPKC (120 Ϯ 24%, p ϭ 0.03; Fig 5) ; however, this effect was not significant versus NTsiRNA ( p ϭ 0.52).
Hypoglossal motor output exhibits AIH-induced LTF, although it is more variable than pLTF, depending on age, sex, and rat colony (Fuller et al., 2000 (Fuller et al., , 2001b Behan et al., 2002; BakerHerman and Strey, 2011) . There was no evidence for unintended (indirect) brainstem effects from intrapleural siRNAs because hypoglossal LTF was unaffected by any of the intrapleural siRNAs tested ( Fig. 6 ; siPKC and siPKC, p Ͼ 0.05 vs NTsiRNA, p Ͻ 0.05 vs time controls). Because there is no direct route for intrapleural siRNAs to reach hypoglossal motor neurons, these data suggest that siRNAs do not have indirect effects, such as trans-synaptic transport to brainstem premotor neurons, which provide the respiratory-related synaptic inputs to hypoglossal motor neurons (Yamada et al., 1988; Woch et al., 2000) .
PKC knockdown in the ventral cervical spinal cord was confirmed with immunoblots of ventral spinal homogenates from the C 3 to C 5 spinal segments (Fig. 7A) . Intrapleural siPKCs significantly decreased PKC protein levels (Ϫ49 Ϯ 18%, p ϭ 0.03) versus rats given NTsiRNAs (Fig. 7B) . As expected, siPKC (Fig. 7C) had no significant effect on PKC protein levels (Ϫ13 Ϯ 15%, p ϭ 0.528 vs NTsiRNA; Fig. 7D ). Thus, intrapleural siPKCs selectively target and knock down ventral spinal PKC, whereas siPKCs had no off-target effects on PKC. These measurements confirm that intrapleural siPKCs selectively reduce PKC expression within the ventral cervical cord encompassing the phrenic motor nucleus and strengthen the argument that PKC is the PKC isoform necessary for pLTF.
Discussion
Here we demonstrate that a single novel PKC isoform, PKC, is necessary for an important form of spinal motor plasticity, AIHinduced pLTF. The role of PKC in pLTF was demonstrated with the following: (1) spinal application of drugs targeting multiple PKC isoforms, but with distinct affinities; (2) a cell-permeable peptide targeting the catalytic site of PKC; and (3) targeted PKC knockdown within phrenic motor neurons via RNA interference. No other known mammalian PKC isoform was required for AIH-induced pLTF. Although PKC is highly expressed in phrenic motor neurons and is also found in unidentified neurons of the ventral cervical spinal cord, there was minimal expression in adjacent glia. Functional, localization of the relevant PKC was achieved with intrapleural siRNAs targeting PKC mRNA; intrapleural injections are accessible to respiratory motor neuron terminals accessing the pleural space, and are retrogradely transported to phrenic motor neuron cell bodies (Mantilla et al., 2009 (Mantilla et al., , 2013 . Although we cannot completely rule out transcellular siRNA exchange as claimed in vitro (Valadi et al., 2007; Mittelbrunn and Sánchez-Madrid, 2012; Montecalvo et al., 2012) , the combination of restricted PKC localization within neurons and the profound effect of intrapleural siPKC on pLTF suggest, at a minimum, that the relevant PKC is within the phrenic motor network. Collectively, our data provide the first evidence that motor neuron PKC is required for any form of spinal plasticity.
Spinal PKC activity is required for pLTF
Using available reagents, we demonstrated that a single spinal PKC isoform (PKC) is required for AIH-induced pLTF. Although mechanisms giving rise to AIH-induced pLTF have been studied extensively in recent years (Dale-Nagle et al., 2010a , 2010b Devinney et al., 2013) , this is the first confirmation of the role played by PKC. PKC activation likely occurs downstream from spinal serotonin Type 2 (5-HT 2 ) receptor activation be- Figure 2 . Dose-responses of intrathecal PKC inhibitors on pLTF. Each group received 12 l intrathecal injections of PKC inhibitor of shown concentrations over the phrenic motor nucleus. A, Gö 6983 had no effect on pLTF at any dose. Amplitude of pLTF at 60 min after AIH in rats given injections of 0.1-2 mM Gö 6983 (n ϭ 7) or 10 mM Gö 6983 (n ϭ 2) compared with rats given vehicle (100% DMSO, n ϭ 7) injections. B, NPC had no effect on pLTF at any dose. Amplitude of pLTF at 60 min after AIH in rats given injections of 100 M NPC15437 (n ϭ 2) or 5-40 mM NPC15437 (n ϭ 7) compared with rats given vehicle (ACSF, n ϭ 3) injections ( p Ͼ 0.05). C, CID755673 had no effect on pLTF at any dose tested. Amplitude of pLTF at 60 min after AIH in rats given injections of 10 M (n ϭ 2), 50 M (n ϭ 2), or 0.2-5 mM CID755673 (n ϭ 3) compared with rats given vehicle (10 -20% DMSO in ACSF, n ϭ 3) injections ( p Ͼ 0.05). D, Sotrastaurin significantly attenuated pLTF. Amplitude of pLTF at 60 min after AIH in rats given injections of 0.2 M (n ϭ 2), 2 M (n ϭ 4), or 20 M sotrastaurin (n ϭ 2) compared with rats given vehicle (10% DMSO in ACSF, n ϭ 2) injections. *Significant difference versus grouped time controls (rats given vehicle or drug with no AIH, n ϭ 13). # Significant difference versus grouped vehicle AIH rats (0%-20% DMSO in ACSF, 100% DMSO with AIH, n ϭ 20).
cause spinal Gq protein-coupled 5-HT 2 receptor activation is both necessary and sufficient for pLTF (Fuller et al., 2001a; MacFarlane and Mitchell, 2009) , and these receptors are highly expressed in phrenic motor neurons (Basura et al., 2001; MacFarlane et al., 2011) . 5-HT 2 receptors activate phospholipase C to produce diacylglycerol and inositol triphosphate (Pandey et al., 1995) . Diacylglycerol binds to the regulatory domain (C1) of PKC, activating the catalytic domain to enable phosphorylation of downstream targets (Steinberg, 2008) . Thus, we suggest that PKC activity is most likely induced by 5-HT 2 receptor activation and subsequent diacylglycerol production within phrenic motor neurons.
PKC differs from all other novel and classical PKC isoforms because it binds diacylglycerol predominantly at the C1B versus the C1A region of the regulatory domain (Melowic et al., 2007; Steinberg, 2008) . Moreover, the C1B region of PKC may be unable to bind NPC because structural studies demonstrate narrowing of the phorbol ester-binding surface of C1B in PKC versus the relatively similar PKC␦ C1B region, which has 80% sequence homology (Rahman et al., 2013) . This difference may explain how NPC, which binds the diacylglycerol binding site of most PKC isoforms (Sullivan et al., 1991) , had no effect on pLTF. Most likely, NPC fails to block PKC because it cannot bind the distinct C1B-diacylglycerol binding-site of PKC. This key difference in PKC regulatory domain structure enabled us to use NPC as a pharmacological tool to rule out other conventional and novel PKC isoforms. Because inhibitors that have no known PKC activity (Gö 6983, CID, NPC) had no effect on pLTF and collectively cover all other known conventional and novel PKC isoforms aside from PKC, it is highly unlikely that any other PKC isoforms are required for pLTF. Thus, our pharmacological studies support the idea that PKC is uniquely required for pLTF.
Cellular localization of pLTF: targeting spinal neurons with siRNAs
Because 5-HT 2 receptors are abundantly expressed on phrenic neurons (Basura et al., 2001; Fuller et al., 2005) , and many molecules associated with pLTF (5-HT 2 receptors, BDNF, TrkB, and phospho-ERK) are upregulated in presumptive phrenic motor neurons following repetitive exposure to acute intermittent hypoxia (Lovett-Barr et al., 2012; , we previously hypothesized that pLTF arises from cellular mechanisms within phrenic motor neurons per se (Fuller et al., 2000; Feldman et al., 2003; Mahamed and Mitchell, 2008; Dale-Nagle et al., 2010b) . However, no studies to date provide direct experimental evidence to support this hypothesis. Here, we used a novel approach, intrapleural siRNA injections and phrenic nerve recordings, to specifically target phrenic motor neurons (Mantilla et al., 2013) . Although the observation that siPKC knockdown within phrenic motor neurons abolishes pLTF is consistent with the idea that the relevant PKC for pLTF is within phrenic motor neurons per se, we cannot completely rule out the possibility of transcel- (Cell Signaling Technology, #9377, green) . B, Colocalization of phrenic motor neurons (CtB, blue) and PKC fluorescence (green) is evident; in contrast, no colocalization could be appreciated between microglia (CD11b, red) and PKC (green) fluorescence. D, Colabeling for phrenic motor neurons (CtB, blue) and astrocytes (GFAP, red) reveals no expression of PKC in astrocytes. The yellow circle outlines the phrenic motor nucleus. E, Higher-magnification images of phrenic motor nucleus demonstrate PKC immunofluorescence (green). F, PKC immunofluorescence is present in phrenic motor neurons (CtB-positive, red; ), but also in unidentified putative neurons near the phrenic motor nucleus (CtB-negative, *). (Fig. 2 B, D) . siPKCs could possibly jump synapses, conceivably affecting . Hypoglossal LTF is unaffected by intrapleural siRNA. Hypoglossal nerve amplitude (% baseline) following AIH exposure after pretreatment with intrapleural injections of nontargeting siRNA (NTsiRNA, n ϭ 5), PKC siRNA (siPKC, n ϭ 3), or PKC siRNA (siPKC, n ϭ 3). All groups were significantly elevated compared with time control rats (NTsiRNA, n ϭ 3; siPKC, n ϭ 2; or siPKC, n ϭ 3 ϩ no AIH, n ϭ 8). *p Ͻ 0.05, significant difference versus time control. . A, Representative immunoblot of ventral C 3 -C 5 spinal cord from rats given three, daily intrapleural injections of nontargeting siRNAs (NTsiRNA, n ϭ 6) or PKC mRNA targeting siRNAs (siPKC, n ϭ 6). The immunoblot was cut (dotted line) and probed for PKC and GAPDH (as a loading control). B, Semiquantitative analysis of optical density (normalized to GAPDH) demonstrates significant PKC knockdown after intrapleural siPKCs (vs NTsiRNA). C, Representative immunoblots for NTsiRNA (n ϭ 4) or PKC mRNA targeting siRNAs (siPKC, n ϭ 3). The immunoblot was cut (dotted line) and probed for PKC and GAPDH (as a loading control). D, Semiquantitative analysis of optical density (normalized to GAPDH) reveals no significant change in PKC protein after intrapleural siPKC (vs NTsiRNA). *p Ͻ 0.05 versus NTsiRNA.
PKC expression in spinal interneurons (Lane et al., 2008; Lane, 2011) or presynaptic modulatory neurons, such as the raphe serotonergic neurons that initiate AIH-induced pLTF Mahamed and Mitchell, 2008; DaleNagle et al., 2010b Intrapleural siRNAs most likely affect other respiratory motor pools that contact the pleural space, such as intercostal motor neurons; indeed, these motor pools retrogradely transport CtB after intrapleural injections (Mantilla et al., 2009) . Because intercostal motor neurons have no direct connections to phrenic motor neurons, there is no reason to believe that intercostal motor neurons will affect pLTF. On the other hand, we suspect that intrapleural siPKC would block intercostal LTF (Fregosi and Mitchell, 1994) , unless there are unknown mechanistic differences between these motor pools. There is some possibility that intrapleural siRNAs are retrogradely transported by the vagus nerve to the dorsal motor nucleus of the vagus or the nucleus ambiguous. Although we cannot rule out PKC knockdown in these areas, it highly unlikely such knockdown (if it occurs) would influence pLTF.
Motor neurons are plastic
Historically, motor neurons have been thought of as simple relays linking the CNS to muscles. Accumulating evidence has suggested that motor neurons are dynamic, including studies on plasticity in the model organism, Aplysia (Glanzman, 2008) . Moreover, spinal motor neurons have extensive dendritic trees, which are influenced by developmental experiences, such as gravitational changes (Inglis et al., 2000) . In the respiratory system, we know of at least five distinct cellular mechanisms giving rise to phrenic motor facilitation (Dale-Nagle et al., 2010a) . Here, we provide evidence that AIH elicits plasticity within motor neurons (and/or their immediate neural network), thereby inducing pLTF. Further, we demonstrate that a single PKC isoform (of 15) is necessary for pLTF, and the relevant PKC is within phrenic motor neurons per se. Further studies aimed at understanding spinal motor neuron plasticity will enable a better understanding of how motor systems adapt to the ever-changing demands of life, such as normal development and aging, gaining or losing weight, changes in physiological conditions, or the onset of disease (Mitchell and Johnson, 2003) .
Clinical significance
Motor plasticity also has therapeutic implications in clinical disorders that compromise both respiratory and nonrespiratory motor function. For example, intermittent hypoxia induces recovery of breathing capacity (Lovett-Barr et al., 2012) as well as rat forelimb (Lovett-Barr et al., 2012) and human leg function (Trumbower et al., 2012) after chronic, incomplete spinal injuries. AIH-induced plasticity may also prove useful in preserving or restoring breathing capacity in patients with motor neuron disease, such as amyotrophic lateral sclerosis . Manipulating key molecules, such as PKC, may enable us to harness motor plasticity to restore motor function, without the concerns and inconveniences involved with hypoxic exposures (Almendros et al., 2014) . Moreover, understanding the role of PKC in plasticity will guide our use of specific PKC inhibitors, which are currently being developed for immunosuppression (Zhang et al., 2013) . Appreciating the role of PKC in plasticity may enable us to predict unintended effects of these agents.
Targeted RNA interference in respiratory motor pools with intrapleural siRNAs may lead to simple and effective therapies in patients with compromised breathing capacity, such as occurs in amyotrophic lateral sclerosis or spinal cord injury. For example, intrapleural siRNAs targeting molecules that restrain motor plasticity might be used to enhance motor output, thereby preserving/restoring some of the lost capacity. In ventilator-dependent patients, increased breathing capacity might enable unassisted ventilation, improving quality of life (Criner, 2002; Martin, 2002) . Because intrapleural siRNAs profoundly affect phrenic motor plasticity, and the technique is relatively noninvasive and well tolerated by rodents, we provide proof of principle that this technique could be useful to implement gene therapy in respiratory motor neurons.
